Cited by 48Spondyloarthritis Studies and TreatmentsOsteoarthritis Treatment and MechanismsGout, Hyperuricemia, Uric Acid

Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis

Chandran, Vinod, Abji, Fatima, Perruccio, Anthony V, Gandhi, Rajiv, Li, Suzanne, Cook, Richard J, Gladman, Dafna D·2019·Annals of the Rheumatic Diseases

Abstract

Objectives We aimed to identify soluble biomarkers that differentiate psoriatic arthritis (PsA) from osteoarthritis (OA).Methods Markers of cartilage metabolism (cartilage oligomeric matrix protein [COMP], hyaluronan), metabolic syndrome (adiponectin, adipsin, resistin, hepatocyte growth factor [HGF], insulin, leptin) and inflammation (C-reactive protein [CRP], interleukin-1β [IL-1β], IL-6, IL-8, tumour necrosis factor alpha [TNFα], monocyte chemoattractant protein-1 [MCP-1], nerve growth factor [NGF]) were compared in serum samples from 201 patients with OA, 77 patients with PsA and 76 controls. Levels across the groups were compared using the Kruskal-Wallis test. Pairwise comparisons were made with Wilcoxon rank-sum test. Multivariate logistic regression analyses were performed to identify markers that differentiate PsA from OA. Receiver operating characteristic (ROC) curves were constructed based on multivariate models. The final model was further validated in an independent set of 73 PsA and 75 OA samples using predicted probabilities calculated with coefficients of age, sex and biomarkers.Results Levels of the following markers were significantly different across the three groups (p<0.001)-COMP, hyaluronan, resistin, HGF, insulin, leptin, CRP, IL-6, IL-8, TNFα, MCP-1, NGF. In multivariate analysis, COMP (OR 1.24, 95% CI 1.06 to 1.46), resistin (OR 1.26, 95% CI 1.07 to 1.48), MCP-1 (OR 1.10, 95% CI 0.07 to 1.48) and NGF (OR<0.001, 95% CI <0.001 to 0.25) were found to be independently associated with PsA versus OA. The area under the ROC curve (AUROC) for this model was 0.99 compared with model with only age and sex (AUROC 0.87, p<0.001). Similar results were obtained using the validation sample.Conclusion A panel of four biomarkers may distinguish PsA from OA. These results need further validation in prospective studies.

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2018-214737

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CFD is involved in pathophysiological mechanisms of osteoarthritis and is considered a potential predictive biomarker of joint pain in patients with hip and knee osteoarthritis.

    “In line with this finding, patients’ cells also showed increased mRNA levels of complement factor D (CFD), a component of the alternative complement pathway [147], which is involved in pathophysiological mechanisms of osteoarthritis and is considered as a potential predictive biomarker of joint pain in patients with hip and knee osteoarthritis [148,149,150].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chandran, V., Abji, F., Perruccio, A. V., Gandhi, R., Li, S., Cook, R. J., & Gladman, D. D.
Affiliations
  • University of Toronto (CA)
  • University Health Network (CA)
  • Toronto Western Hospital (CA)
  • University of Waterloo (CA)
Corresponding author
Gladman, Dafna D
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2019-06
Volume
78
Issue
6
Pages
796-801
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2942307919
Cited by
48
References
39
Citations by year
2026: 5 · 2025: 2 · 2024: 7 · 2023: 10 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 3
FWCI
4.56
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of the Rheumatic Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
Keywords
psoriatic arthritis, osteoarthritis, serum biomarkers, differential diagnosis, cartilage oligomeric matrix protein, hyaluronic acid, resistin, hepatocyte growth factor, nerve growth factor, MCP-1, inflammatory cytokines, metabolic syndrome, C-reactive protein, biomarker panel, disease classification, diagnostic accuracy, leptin, adiponectin
MeSH terms
Adult, Aged, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Osteoarthritis, ROC Curve, Severity of Illness Index, Solubility, Reproducibility of Results, Biomarkers, Arthritis, Psoriatic, Chemokine CCL2, Nerve Growth Factor, Resistin, Cartilage Oligomeric Matrix Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review